Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 4/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16687029 | 0.82 | SCN4A (0.42) | MAPTNPC1RAB9APOLBNPSR1 | |
| SCHEMBL23638350 | 0.81 | NPC1 (0.37) | MAPTNPC1RAB9APOLBNPSR1 | |
| Methane SCHEMBL19031863 | 0.81 | SCN4A (0.41) | MAPTNPC1RAB9APOLBNPSR1 | |
| SCHEMBL28026546 | 0.78 | LMNA (0.40) | MAPTNPC1RAB9APOLBLMNA | |
| SCHEMBL32666116 | 0.77 | MAPT (0.43) | MAPTNPC1RAB9ANPSR1MAPK1 | |
| SCHEMBL28684123 | 0.74 | NOS1 (0.53) | MAPTNPC1RAB9APOLBNPSR1 | |
| Bicarbonate SCHEMBL5617163 | 0.74 | NPC1 (0.43) | MAPTNPC1RAB9APOLBLMNA | |
| SCHEMBL27257093 | 0.74 | PRMT6 (0.36) | MAPTNPC1RAB9APOLBNPSR1 | |
| SCHEMBL3398022 | 0.72 | — | — | |
| SCHEMBL1120263 | 0.72 | LMNA (0.50) | MAPTPOLBLMNAKDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2632551-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | claimed |
| WO-2012058132-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | claimed |
| US-10093630-B2 | Pyrazole compounds and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-07-06 | — | — | US | disclosed |
| EP-2632551-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012058132-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, FAAH, FAAH2 | MAPT 4504/4885NPC1 3019/4885RAB9A 1540/4885 |
| US-10093630-B2 | Pyrazole compounds and methods of making and using same | ABHD6, FAAH, FAAH2 | MAPT 4504/4885NPC1 3019/4885RAB9A 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.